A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT Number: NCT04969913
Background:
Half of the world s population is at risk of malaria. In 2015, there were 214 million cases of malaria and 438,000 deaths. A transmission-blocking vaccine (TBV) could help end the disease. Improved tests are needed to measure how well the vaccines work. Researchers want to collect data about malaria infection as the first step in testing a TBV in rural Guinea.
Objective:
To study community dynamics of malaria transmission by estimating the rate of blood smear positive people by month and season.
Eligibility:
People 6 months of age and older who live in Maf(SqrRoot)(Registered Trademark)rinyah sub-prefecture and plan to remain during the study. Households with at least 3 people who are eligible to take part in the study are also needed.
Design:
Participants will be screened with a medical and medicine history. They will have a physical exam. Their height and weight will be measured. Their vital signs may be taken.
Participants will have a study visit each month for up to 3 years. They will get a study ID. They will be asked about any symptoms of malaria or changes in health. They will give blood samples. They may have a physical exam. Within 3 days of the study visits, live and dead mosquitoes may be gathered in and around their home. Insecticide spray will be used.
Participants can visit the clinic at any time if they feel ill. If they have malaria, they will be treated according to Guinea National Malaria Control Guidelines for adults and children.
Looking for future studies?
Notify Me6 month and older
All sexes
Observational
Maferinyah Rural Health Training and Research Center, Maferinyah, Guinea
A vaccine that interrupts malaria transmission is critical to eradicate the disease, but improved assays are needed to measure the efficacy of vaccines. Transmission-blocking vaccines (TBVs) work by inducing antibodies that inhibit parasite development in the mosquito interrupting transmission. Efficacy of vaccines may be estimated by in vitro membrane feeding assays using immune sera and laboratory mosquitoes, but qualified assays that measure transmission in the field are needed to assess transmission-blocking interventions in natura.
Clinical trials of TBVs have started elsewhere on the continent in Mali, and we expect to expand TBV studies in Guinea in the near future. This protocol will use a longitudinal cohort to gather information of malaria transmission based on the rates of blood smear positive individuals by month, season and year in at Maferinyah sub-prefecture, Guinea.
Individuals in the villages will be approached first for participation, including permission to contact their household and neighbors of their compound for participation. Households will be identified using census data and individuals will be consented for participation.
Malaria smears will be obtained at monthly visits, in conjunction with mosquito collections in/around village residences. Parasite infection rates in locally caught mosquitoes will be assessed longitudinally for differences by season and year. A total of 400 volunteers from Maferinyah will be enrolled. Participants will be followed for up to 3 years, to collect data that will guide the design of future community-based trials of TBV.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
HOUSEHOLD INCLUSION CRITERIA:
To be eligible for participation, households must meet the following criteria:
SUBJECT EXCLUSION CRITERIA:
Time frame: Season and year
Rate of blood smear positive individuals by month and season stratified by age
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT04650815
Infections, Malaria
Sabou, Burkina Faso
View Trial DetailsNCT03719599
Infections, Inflammation
Margibi, Liberia
View Trial DetailsNCT05979207
Anti-Infective Agents, Antimalarials
Brisbane, Queensland, Australia
View Trial Details